Study on levels of hs-CRP in Acute Coronary Syndrome

Abstract

INTRODUCTION: CAD includes a variety of conditions resulting from sudden reduction or interruption the heart's blood flow. This spectrum includes unstable angina, NSTEMI, and STEMI. quick diagnosis and management are essential in ACS to minimize myocardial damage and improve outcomes. Among the various biomarkers used to assess ACS, Hs-CRP has emerged as a important player in evaluating cardiovascular risk and guiding treatment strategies. One is coronary heart disease, or CHD. of the leading causes of mortality and morbidity all over the world, including India. Hs-CRP is currently employed for risk assessment and primary prevention of atherosclerotic cardiovascular disease (ASCVD), there is a scarcity of information regarding the association between Hs-CRP levels in patients presenting with ACS and their association with outcomes. Studying hscrp levels in patients presenting with acute coronary syndrome is crucial for assessing inflammation's role in the condition. This investigation aids in identifying dormant markers for risk stratification and contributes to a better understanding of cardiovascular risk factors. Therefore, our research was started to evaluate the levels of hs crp in patients with acute coronary syndrome. AIM: To investigate the relationship between ACS patients' hs-crp levels and its relation with CAD risk factors. OBJECTIVES: To investigate the relationship between ACS patients' hs-crp levels .To study the demographic status of the patients presenting with ACS. To study the cardiac enzymes (creatine kinase- myocardial band, troponin I),resting 12‑lead electrocardiogram of patient diagnosed with ACS. To detect the severity of ACS with laboratory parameters(CK-MB, trop I) and electrocardiogram (STEMI vs NSTEMI). METHODOLOGY: This Cross-Sectional Observational study conducted in single center at KIMS Deemed To Be University, Karad, Maharashtra.110 individual with CAD more than 18 years age and both sex, who were admitted in KVV and hospital ICCU and IMCU were involved in our study over a period of 18 months from 2nd September 2022 to 29th February 2024. RESULTS: Markers differ significantly across groups: hs-CRP levels are highest in STEMI (3.70 ± 0.69 mg/l) and NSTEMI (3.55 ± 0.86 mg/l) compared to UA (2.4 ± 0.38 mg/l) and Control (1.86 ± 0.53 mg/l), P < 0.0001. CK-MB is elevated in STEMI (3.35 ± 5.32 ng/ml) and NSTEMI (3.41± 6.29 ng/ml) over UA (1.52 ± 2.99 ng/ml) and Control (1.52 ± 0.99 ng/ml), P < 0.0001. Troponin I is highest in STEMI (4.96 ± 7.72 ng/ml) and NSTEMI (5.99 ± 8.12 ng/ml) compared to UA (0.56 ± 0.64 ng/ml) and Control (0.23 ± 0.82 ng/ml), P = 0.003. Conclusion: The study highlights hs-CRP as a valuable biomarker for diagnosing acute coronary syndrome, stratifying patient risk, and identifying those at higher risk for more intensive treatment.
Categories: Internal Medicine